Firebrick Pharma Ltd (FRE) - Total Liabilities
Based on the latest financial reports, Firebrick Pharma Ltd (FRE) has total liabilities worth AU$341.73K AUD (≈ $241.79K USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore FRE shareholders equity momentum to track the company's year-over-year net asset growth rate.
Firebrick Pharma Ltd - Total Liabilities Trend (2019–2025)
This chart illustrates how Firebrick Pharma Ltd's total liabilities have evolved over time, based on quarterly financial data.
Firebrick Pharma Ltd Competitors by Total Liabilities
The table below lists competitors of Firebrick Pharma Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
PVW Resources Ltd
AU:PVW
|
Australia | AU$1.02 Million |
|
Purple Biotech Ltd
TA:PPBT
|
Israel | ILA6.25 Million |
|
OurLiving AB
ST:OURLIV
|
Sweden | Skr8.99 Million |
|
KC Property PLC
BK:KC
|
Thailand | ฿692.37 Million |
|
Emico Holdings Bhd
KLSE:9091
|
Malaysia | RM33.16 Million |
|
Eversafe Rubber Bhd
KLSE:0190
|
Malaysia | RM49.46 Million |
|
Whitebark Energy Ltd
AU:WBE
|
Australia | AU$5.06 Million |
|
Elkop SA
WAR:EKP
|
Poland | zł22.00K |
Liability Composition Analysis (2019–2025)
This chart breaks down Firebrick Pharma Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Firebrick Pharma Ltd (FRE) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.32 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Firebrick Pharma Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Firebrick Pharma Ltd (2019–2025)
The table below shows the annual total liabilities of Firebrick Pharma Ltd from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$271.28K ≈ $191.95K |
-6.80% |
| 2024-06-30 | AU$291.07K ≈ $205.95K |
-42.53% |
| 2023-06-30 | AU$506.44K ≈ $358.34K |
+12.52% |
| 2022-06-30 | AU$450.10K ≈ $318.47K |
+109.54% |
| 2021-06-30 | AU$214.80K ≈ $151.98K |
-18.70% |
| 2020-06-30 | AU$264.22K ≈ $186.95K |
+170.68% |
| 2019-06-30 | AU$97.61K ≈ $69.07K |
-- |
About Firebrick Pharma Ltd
Firebrick Pharma Limited engages in the development and commercialization of povidone-iodine (PVP-I) products under the Nasodine brand in Asia, North America, Europe, and internationally. It offers nasal spray PVP-I products for the treatment of common cold. The company was incorporated in 2012 and is based in Melbourne, Australia.